Guardant Health, Inc. (NASDAQ:GH) Receives Consensus Rating of “Buy” from Analysts

Shares of Guardant Health, Inc. (NASDAQ:GHGet Free Report) have received a consensus recommendation of “Buy” from the twenty-one ratings firms that are covering the stock, Marketbeat reports. Twenty research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12-month target price among brokers that have issued a report on the stock in the last year is $53.29.

GH has been the subject of several recent research reports. Piper Sandler restated an “overweight” rating and issued a $60.00 price target (up from $50.00) on shares of Guardant Health in a research report on Tuesday, May 6th. JPMorgan Chase & Co. increased their price objective on Guardant Health from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Friday, February 21st. Canaccord Genuity Group raised their target price on Guardant Health from $60.00 to $65.00 and gave the stock a “buy” rating in a research report on Thursday, May 1st. UBS Group upped their price target on Guardant Health from $65.00 to $70.00 and gave the company a “buy” rating in a research report on Thursday, May 1st. Finally, Raymond James reissued an “outperform” rating and issued a $59.00 price target (up previously from $39.00) on shares of Guardant Health in a research note on Friday, February 21st.

Check Out Our Latest Report on GH

Insider Transactions at Guardant Health

In other news, CEO Amirali Talasaz sold 106,784 shares of the company’s stock in a transaction dated Thursday, May 1st. The shares were sold at an average price of $49.01, for a total transaction of $5,233,483.84. Following the transaction, the chief executive officer now owns 2,202,672 shares in the company, valued at approximately $107,952,954.72. This represents a 4.62% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders sold a total of 107,232 shares of company stock valued at $5,252,559 in the last quarter. 6.10% of the stock is currently owned by company insiders.

Institutional Trading of Guardant Health

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. increased its position in Guardant Health by 3.0% in the 4th quarter. Vanguard Group Inc. now owns 12,052,551 shares of the company’s stock valued at $368,205,000 after buying an additional 350,606 shares in the last quarter. Deep Track Capital LP increased its position in Guardant Health by 7.0% in the 4th quarter. Deep Track Capital LP now owns 6,419,566 shares of the company’s stock valued at $196,118,000 after buying an additional 419,006 shares in the last quarter. Invesco Ltd. increased its position in Guardant Health by 100.9% in the 1st quarter. Invesco Ltd. now owns 2,794,667 shares of the company’s stock valued at $119,053,000 after buying an additional 1,403,670 shares in the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its position in Guardant Health by 6.3% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,777,040 shares of the company’s stock valued at $118,302,000 after buying an additional 164,263 shares in the last quarter. Finally, Two Sigma Advisers LP increased its position in Guardant Health by 96.7% in the 4th quarter. Two Sigma Advisers LP now owns 2,315,600 shares of the company’s stock valued at $70,742,000 after buying an additional 1,138,300 shares in the last quarter. 92.60% of the stock is owned by institutional investors.

Guardant Health Stock Down 0.7%

Shares of GH opened at $48.06 on Monday. The stock has a market cap of $5.95 billion, a PE ratio of -13.50 and a beta of 1.37. Guardant Health has a 12-month low of $20.14 and a 12-month high of $52.92. The business has a 50-day simple moving average of $42.93 and a two-hundred day simple moving average of $41.13.

Guardant Health (NASDAQ:GHGet Free Report) last released its quarterly earnings data on Wednesday, April 30th. The company reported ($0.49) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.57) by $0.08. The company had revenue of $203.47 million during the quarter, compared to the consensus estimate of $189.91 million. Guardant Health had a negative return on equity of 19,157.20% and a negative net margin of 59.05%. The firm’s revenue was up 20.8% compared to the same quarter last year. During the same quarter in the prior year, the firm posted ($0.46) earnings per share. On average, equities research analysts expect that Guardant Health will post -2.9 EPS for the current year.

Guardant Health Company Profile

(Get Free Report

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.

Featured Stories

Analyst Recommendations for Guardant Health (NASDAQ:GH)

Receive News & Ratings for Guardant Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Guardant Health and related companies with MarketBeat.com's FREE daily email newsletter.